"Quinazolinones" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Chemicals with two conjoined aromatic rings incorporating two nitrogen atoms and one of the carbons oxidized with a keto oxygen.
| Descriptor ID |
D052999
|
| MeSH Number(s) |
D03.633.100.786.830
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Quinazolinones".
Below are MeSH descriptors whose meaning is more specific than "Quinazolinones".
This graph shows the total number of publications written about "Quinazolinones" by people in this website by year, and whether "Quinazolinones" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Quinazolinones" by people in Profiles.
-
Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. JCI Insight. 2019 07 23; 5.
-
Targeting the PI3K pathway in cancer: are we making headway? Nat Rev Clin Oncol. 2018 05; 15(5):273-291.
-
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018 04 12; 131(15):1704-1711.
-
Phase II study of idelalisib, a selective inhibitor of PI3Kd, for relapsed/refractory classical Hodgkin lymphoma. Ann Oncol. 2017 May 01; 28(5):1057-1063.
-
Idelalisib and bendamustine combination is synergistic and increases DNA damage response in chronic lymphocytic leukemia cells. Oncotarget. 2017 Mar 07; 8(10):16259-16274.
-
NK cells converge lytic granules to promote cytotoxicity and prevent bystander killing. J Cell Biol. 2016 Dec 19; 215(6):875-889.
-
Idelalisib in Waldenstr?m macroglobulinemia: high incidence of hepatotoxicity. Leuk Lymphoma. 2017 04; 58(4):1002-1004.
-
Idelalisib Impacts Cell Growth through Inhibiting Translation-Regulatory Mechanisms in Mantle Cell Lymphoma. Clin Cancer Res. 2017 Jan 01; 23(1):181-192.
-
Idelalisib in the management of lymphoma. Blood. 2016 07 21; 128(3):331-6.
-
Outcomes of patients with chronic lymphocytic leukemia treated with first-line idelalisib plus rituximab after cessation of treatment for toxicity. Cancer. 2016 08 15; 122(16):2505-11.